New Diagnostics Working Group

Annual Meeting 2015

3 December 2015
9:00 - 12:30

Roof Terrace Room, Level 2,
CTICC, Cape Town, South Africa

Chairpersons
Daniela Cirillo, San Raffaele Scientific Institute
Bill Rodriguez, FIND
NDWG Co-Chairs

About the NDWG
The New Diagnostics Working Group (NDWG) is one of the seven working groups of the Stop TB Partnership. Its mission is to foster development and evaluation of new diagnostics for tuberculosis by serving as a coordination, communication and advocacy platform for all stakeholders in TB diagnostic research and development. The NDWG provides a neutral and overarching platform for coordination at the global level.

Symposium

Overview
This annual meeting will review three main areas of activity in which the NDWG has engaged to advance TB diagnostic research and development.

In the first session we will examine the promises of next generation sequencing for detection of anti-microbial resistance and present progress on the development of the ReSeqTB data sharing platform.

Presentations in the second session will discuss the new priorities for drug susceptibility testing in order to ensure the successful adoption of new TB drug regimens and highlight the role of laboratory-based approaches.

The third session will focus on the development of tests for progression of latent TB to active disease, which are required to efficiently introduce targeted preventive therapy and support the goal of TB elimination. In particular, we will report on the outcomes of an expert meeting organized by the NDWG in collaboration with partners and share the latest updates on the development of target product profiles and study protocols.

Agenda overleaf
Agenda
NDWG Annual Meeting 2015

9:00-10:00  -  Part I

Use of next generation sequencing for detection of anti-microbial resistance

Welcome and introduction, Daniela Cirillo and Bill Rodriguez

- Scaling up sequencing in order to determine sequence diversity worldwide and for the identification of genetic variants that confer resistance to all old and new anti-mycobacterial drugs
  Derrick Crook, Nuffield Department of Medicine, University of Oxford
- The ReSeqTB initiative and recent progress in the development of the data sharing platform
  Angela Starks, US Centers for Disease Control and Prevention
- User-friendly platforms for large data analysis
  Stefan Niemann, Research Center Borstel
- Q&A

Coffee break 10:00-10:30

10:30-11:20  -  Part II

New TB drug regimens and new priorities for DST

- DST for Delamanid and quality control
  Daniela Cirillo, San Raffaele Scientific Institute
- Laboratory-based DST for Bedaquiline and introduction in countries
  Leen Rigouts, Antwerp Institute of Tropical Medicine
- Genetic diversity within MTB for the development of new DST
  Claudio Köser, Department of Medicine, University of Cambridge
- Q&A

11:20-12:30  -  Part III

Biomarker research and development of tests for progression of latent TB to active disease

- Diagnostic and prognostic markers of progression to active disease: Progress and needs
  Mark Hatherill, South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town
- Target Product Profile for a test for progression of tuberculosis infection
  Claudia Denkinger, FIND
- New predictive tests for the diagnosis of tuberculosis infection: How should they be evaluated and what evidence is needed for WHO endorsement
  Frank Cobelens, KNCV and AIGHD
- Discussion

Wrap-up and close of the meeting, Daniela Cirillo and Bill Rodriguez